Suppr超能文献

肝移植术后维持免疫抑制治疗中隔日使用泼尼松。

Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.

作者信息

Pedrosa M C, Rohrer R M, Kaplan M M

机构信息

Division of Gastroenterology, New England Medical Center Hospitals, Boston, USA.

出版信息

Clin Transplant. 1995 Aug;9(4):322-5.

PMID:7579741
Abstract

Glucocorticoids have been an important part of maintenance immunosuppressive therapy following orthotopic liver transplantation (OLT). However, long-term daily glucocorticoid use is associated with a high incidence of unpleasant side effects. In an effort to minimize side effects while maintaining adequate immunosuppression, we have treated 48 adult patients with low dose alternate-day prednisone, 15 mg q.o.d. Pre-OLT diagnoses included primary biliary cirrhosis (16 patients), alcoholic liver disease (8 patients), sclerosing cholangitis (8 patients), cryptogenic cirrhosis and/or non-A, non-B hepatitis (11 patients), acute hepatic failure (3 patients), and hepatocellular carcinoma and bile duct carcinoma (1 patient each). Conversion to alternate-day prednisone was attempted when patients were clinically stable and the daily prednisone dose was 15 mg. The average interval between OLT and beginning of the conversion to alternate-day prednisone was 38 weeks. The mean time for conversion to alternate-day prednisone was 35 weeks, but decreased as more experience was gained. The mean follow-up was 106 weeks. Cushingoid side effects diminished in all. In 47 of the 48 patients, there were no clinical laboratory or histologic changes suggestive of rejection after the initiation of alternate-day prednisone. A single episode of rejection occurred during the taper. This episode responded promptly to increased glucocorticoid therapy, and the patient was easily converted to alternate-day prednisone at a later date. There was no increase in concurrent immunosuppressives dosage after the conversion. Alternate-day prednisone is effective and safe for chronic immunosuppression after OLT in patients receiving cyclosporine and azathioprine.

摘要

糖皮质激素一直是原位肝移植(OLT)后维持免疫抑制治疗的重要组成部分。然而,长期每日使用糖皮质激素会带来较高的不良副作用发生率。为了在维持足够免疫抑制的同时尽量减少副作用,我们对48例成年患者采用低剂量隔日泼尼松治疗,剂量为每日15mg,隔日一次。OLT术前诊断包括原发性胆汁性肝硬化(16例)、酒精性肝病(8例)、硬化性胆管炎(8例)、隐源性肝硬化和/或非甲非乙型肝炎(11例)、急性肝衰竭(3例)以及肝细胞癌和胆管癌(各1例)。当患者临床稳定且每日泼尼松剂量为15mg时,尝试转换为隔日泼尼松治疗。OLT与开始转换为隔日泼尼松治疗之间的平均间隔为38周。转换为隔日泼尼松治疗的平均时间为35周,但随着经验的增加而缩短。平均随访时间为106周。所有患者的库欣样副作用均减轻。48例患者中有47例在开始隔日泼尼松治疗后,临床实验室检查或组织学检查均未出现提示排斥反应的变化。在减量过程中发生了一次排斥反应。该次排斥反应对增加的糖皮质激素治疗反应迅速,且患者随后很容易转换为隔日泼尼松治疗。转换后同时使用的免疫抑制剂剂量没有增加。对于接受环孢素和硫唑嘌呤治疗的OLT术后患者,隔日泼尼松用于慢性免疫抑制是有效且安全的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验